What Researchers Did
Researchers conducted a review to examine the process of diabetic wound healing, current treatments, and the potential of in situ gelling injectable hydrogels.
What They Found
The review highlights that about 25% of patients with diabetes are expected to develop diabetic wounds and may face limb amputations. Current treatments often have limitations like pain, frequent dressing changes, high failure rates, and cost. In situ gelling injectable hydrogels show promise for delivering medications and filling wound defects due to their easy encapsulation and prolonged release.
What This Means for Canadian Patients
Canadian patients with diabetic wounds currently face challenges with existing treatments, including pain and high costs. The development of in situ gelling injectable hydrogels could offer a less invasive and more effective way to deliver medications directly to wounds, potentially improving healing outcomes and reducing the need for frequent dressing changes.
Canadian Relevance
This study is not Canadian. However, it covers diabetic wounds, which are a Health Canada-recognized indication for hyperbaric oxygen therapy (HBOT) when they are diabetic foot ulcers. HBOT is also listed as a Medical Subject Heading (MeSH) term for this review.
Study Limitations
As a review, this study summarizes existing research rather than presenting new clinical data or specific HBOT protocols.